Chronic hepatitis C virus infection

Related records

Broader conditions (18)

• Digestive system disorder
• Digestive system infectious disorder
• Disease
• Disease by body system or component
• Disease by developmental or physiological process
• Disease by etiologic mechanism
• Disease of primarily extrinsic mechanism
• Endocrine system disorder
• Hepatitis
• Hepatitis C virus infection
• Hepatobiliary disorder
• Human disease
• Infectious disease
• Inflammatory disease
• Liver disorder
• Primary viral infectious disease
• Viral hepatitis
• Viral infectious disease

Trials (1,046)

• 'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
• "Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt
• 100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)
• 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
• 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
• 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
• 4-Methylumbelliferone as a Treatment for Chronic HBV/HCV
• 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C
• 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)
• 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)
• 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis
• A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
• A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
• A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
• A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
• A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)
• A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects
• A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
• A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Approved drugs (23)

• Boceprevir
• Daclatasvir dihydrochloride
• Dasabuvir sodium monohydrate
• Elbasvir
• Eltrombopag choline
• Eltrombopag olamine
• Glecaprevir
• Grazoprevir anhydrous
• Interferon alfa-2B
• Interferon alfacon-1
• Ledipasvir
• Ombitasvir
• Paritaprevir
• Peginterferon alfa-2A
• Peginterferon alfa-2B
• Pibrentasvir
• Ribavirin
• Ritonavir
• Simeprevir sodium
• Sofosbuvir

Drugs in development (106)

• ABT-072 Phase 2
• Adafosbuvir Phase 2
• Albinterferon alfa-2B Phase 3
• Alisporivir Phase 3
• Amantadine Phase 3
• Asunaprevir Phase 3
• Balapiravir Phase 2
• Baminercept Phase 1
• Beclabuvir Phase 2
• Bemnifosbuvir sulfate Phase 2
• Betaine Early phase 1
• BILB-1941 Phase 1
• BMS-929075 Phase 1
• Bulevirtide Phase 3
• Caffeine Phase 1
• Celgosivir Phase 2
• Chlorcyclizine hydrochloride Phase 1
• Colchicine Phase 2
• CTS-1027 Phase 2
• Cyclosporine Phase 3

Other linked drugs (3)

• Grazoprevir
• Norucholic acid
• Taurursodiol